Alport syndrome is a hereditary chronic kidney disease, attributed to rare pathogenic variants in either of three collagen genes ( COL4A3/4/5 ) with most localized in COL4A5 . Trimeric type IV Collagen α3α4α5 is essential for the glomerular basement membrane that forms the kidney filtration barrier. A means to functionally assess the many candidate variants and determine pathogenicity is urgently needed. We used Drosophila , an established model for kidney disease, and identify Col4a1 as the functional homolog of human COL4A5 in the fly nephrocyte (equivalent of human podocyte). Fly nephrocytes deficient for Col4a1 showed an irregular and thickened basement membrane and significantly reduced nephrocyte filtration function. This phenotype was restored by expressing human reference (wildtype) COL4A5 , but not by COL4A5 carrying any of three established pathogenic patient-derived variants. We then screened seven additional patient COL4A5 variants; their ClinVar classification was either likely pathogenic or of uncertain significance. The findings support pathogenicity for four of these variants; the three others were found benign. Thus, demonstrating the effectiveness of this Drosophila in vivo kidney platform in providing the urgently needed variant-level functional validation.
Competing Interests: COMPETING INTERESTS B.A.W. is a member of the Medical Advisory Board of the Alport Syndrome Foundation and serves as a consultant to the following companies: Bayer, GlaxoSmithKline, Roche, and Amgen. The other authors declare no competing interests.